Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 6Recruiting 3Withdrawn 2Terminated 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 19Sarcoma 6Other solid neoplasm 2Genitourinary 2Gastrointestinal 2Endocrine 2Dermatologic 2Thoracic 1NET 1Lymphoid 1Gynecologic 1

Conditions

Wilms Tumor 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroectodermal Tumors 1Medulloblastoma 1Hereditary leiomyomatosis and renal cell cancer 1Glioma 1Ependymoma 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 19Docetaxel 16Magnetic Resonance Spectroscopy 14Prednisone 13Radiotherapy 11bicalutamide 10Leuprolide 10Abiraterone Acetate 9Radiosurgery 8Cyclophosphamide 8Biopsy 8avelumab 7atezolizumab 6Specimen Handling 6Interleukin-2 6Gemcitabine 6Bevacizumab 6Androgen Antagonists 6tremelimumab 5gallium 68 PSMA-11 5apalutamide 5acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Surveys and Questionnaires 5Sunitinib 5Paclitaxel 5Metformin 5Injections 5Goserelin 5Cisplatin 5ALT-803 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Temozolomide × Genitourinary × Clear all
NCT04603365 2023-05-17

Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell

NCT02689336 2019-09-09

Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors

Washington University School of Medicine

Phase 2 Withdrawn
CNSGenitourinarySarcoma

Ependymoma, Glioma, Medulloblastoma, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡